In conclusion, we suggest that increased tumor microenvironment stiffness leads to stromal cell magnification of the pro-oncogenic function of TGF-β through thus far unrecognized induction and utilization of activin A signaling that may represent a potential therapeutic target in advanced stage CRC. Here, TGFB1 is linked to neoplasm.